Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Amneal Pharmaceuticals, Inc. incurred senior notes of $600 million aggregate principal amount with Wilmington Savings Fund Society, FSB, as trustee and collateral agent at 6.875% maturing August 1, 2032.
- Instrument
- senior notes
- Principal
- $600 million aggregate principal amount
- Counterparty
- Wilmington Savings Fund Society, FSB, as trustee and collateral agent
- Rate
- 6.875%
- Maturity
- August 1, 2032
- Event
- incurrence
Exact text from the filing
completed the previously announced offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 (the “Notes”)
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Amneal Pharmaceuticals, Inc. incurred term loan of $2.1 billion with JPMorgan Chase Bank, N.A., as administrative agent at term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec maturing August 1, 2032.
- Instrument
- term loan
- Principal
- $2.1 billion
- Counterparty
- JPMorgan Chase Bank, N.A., as administrative agent
- Rate
- term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec
- Maturity
- August 1, 2032
- Event
- incurrence
Exact text from the filing
On August 1, 2025, Amneal Pharmaceuticals, Inc.’s (the “Corporation”) subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Issuer”) borrowed $2.1 billion of new seven-year term B loans (the “New Term Loan”) pursuant to an amendment to the Company’s existing term loan credit facility
View on SEC.gov